Aug 7, 2024, 10:50 | Insight

Lorenza Rimassa: Outcomes in patients with unresectable HCC treated with STRIDE

Lorenza Rimassa, Associate Professor of Medical Oncology at HUNIMED, shared on X: "Glad to discuss…

Jul 17, 2024, 09:44 | Societies

7 interviews summarizing study results from ESMOGI24

The European Society for Medical Oncology (ESMO) shared on LinkedIn: "The Breaking Science in Gastrointestinal…

Jul 9, 2024, 21:43 | Blog

All interviews will be available on Oncology Pro from ESMOGI24

ESMO shared on X: "Oncology Pro was onsite in Munich, interviewing key authors about their groundbreaking…

Jul 7, 2024, 18:32 | Blog

A significant perception gap between patients with Colorectal Cancer and Healthcare Professionals - ESMO

ESMO - European Society for Medical Oncology shared a post on LinkedIn: . "A recent…

Jul 3, 2024, 05:47 | Societies

Keynote lecture on liver cancer by Stephen L Chan

Lorenza Rimassa, Associate Professor of Medical Oncology at HUNIMED, shared on X: "Ready for the…

Jul 2, 2024, 17:21 | Blog

Amalya Sargsyan: One of Oncodaily’s top 10 promising drugs is showing great resuts at ESMOGI24

Amalya Sargsyan shared a post by Pashtoon Kasi, on LinkedIn: "Exciting Updates! 𝐁𝐨𝐭𝐞𝐧𝐬𝐢𝐥𝐢𝐦𝐚𝐛 one of OncoDaily's…

Jul 2, 2024, 14:34 | Blog

All disease begins in the gut

Rodrigo Dienstmann, Oncology Data Scientist at VHIO Digital Health, shared on X: "'All disease begins in…

Jul 2, 2024, 14:21 | Blog

Myriam Chalabi: Juan O'Connor putting NEST-1 and ECOG /study into perspective

Myriam Chalabi shared on X: "Great discussion by Juan OConnor in the mini-oral session ESMOGI24. Putting…

Jul 2, 2024, 11:58 | Blog

Nikolas Naleid: Prognostic role of ctDNA in oligometastatic CRC at ESMOGI24

Nikolas Naleid, Internal Medicine PGY3 resident at Case Western Reserve/UH Cleveland Medical Center, shared on X:…

Jul 2, 2024, 09:22 | Societies

Inspired by engaging with the GI community at ESMOGI24 - Agenus

Agenus shared on LinkedIn: "That's a wrap on ESMOGI24! Our team was inspired by engaging…

Jul 2, 2024, 07:19 | Societies

25 Posts You Should Not Miss From ESMOGI24!

ESMOGI24 took place as an onsite event in Munich, Germany, from 26 to 29 June…

Jul 1, 2024, 02:54 | Blog

Erman Akkus: Take home messages from Proffered Papers session at ESMOGI24

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X: “Take home…

Jul 1, 2024, 02:25 | Blog

Insights from ESMOGI24 by Cathy Eng

ESMO GI 2024 took place from June 26 to 29 in Munich, Germany, featuring both…

Jun 30, 2024, 08:07 | Societies

9 Posts You Should Not Miss From Day 3 of ESMOGI24!

ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024,…

Jun 30, 2024, 03:43 | Blog

Pashtoon Kasi: Curative potential of immunotherapy for both MSS and MSI-High tumors

Pashtoon Kasi shared on X: "NEST Trial responses to date. What’s particularly of note is…

Jun 30, 2024, 03:28 | Blog

Erika Ruiz-Garcia: GI oncology team from National Institute of Cancerology will present 6 posters at ESMOGI24

Erika Ruiz-Garcia, Chief of the Translational Medicine Laboratory at the National Institute of Cancerology in Mexico…

Jun 29, 2024, 14:24 | Societies

KRAS - the most commonly mutated oncogene in cancer

Amol Akhade shared on X: "KRAS - the most commonly mutated oncogene in cancer. Nice…

Jun 29, 2024, 13:41 | Societies

ESMOGI24 Key Insights Shared By Megan Barnet

ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29…

Jun 29, 2024, 13:12 | Societies

Poster on early-onset CCA won Best Poster at ESMOGI24

Natalia Tissera, PhD Student at Vall d'Hebron Institute of Oncology (VHIO), shared on X: "Thrilled…

Jun 29, 2024, 12:39 | Societies

Rachel Riechelmann: Excellent discussion of neoadjuvant IO in colorectal cancer

Rachel Riechelmann shared on X: "Excellent discussion of neoadjuvant IO in colorectal cancer by Juan O'Connor…

Jun 29, 2024, 11:21 | Societies

Highlights from ESMOGI24 by Angela Lamarca

ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29…

Jun 29, 2024, 11:05 | Societies

Neoadjuvant botensilimab and balstilimab in colorectal cancer

Smitha Krishnamurthi, Gastrointestinal medical oncologist at Cleveland Clinic, shared on X: "Neoadjuvant botensilimab (1 dose)…

Jun 29, 2024, 10:55 | Societies

Zev Wainberg discussing the 3-year OS data from the TOPAZ-1 trial

Lorenza Rimassa, Associate Professor of Medical Oncology at HUNIMED, shared on X: "Zev Wainberg discussing…

Jun 29, 2024, 10:49 | Societies

The role of gut microbiome in cancer at ESMOGI24

ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024,…

Jun 29, 2024, 10:24 | Societies

Magnus Nilsson discusses when and why we should operate in esophageal cancer

Lizzy Smyth, Consultant Medical Oncologist in upper GI oncology at Oxford University, shared on X:…

Jun 29, 2024, 09:23 | Societies

Unanswered questions in TNT and organ preservation of rectal cancer

Rasha Aboelhassan shared on LinkedIn: "What ever we do? And how much patients we recruit?…

Jun 29, 2024, 06:16 | Societies

Microbiome Research is reshaping colorectal cancer treatment

ESMO shared on LinkedIn: "ESMOGI24: Since the development of Colorectal Cancer (CRC) is intertwined with…

Jun 29, 2024, 00:48 | Blog

Jenny Seligmann: Privilege to share the stage with Jeanne Tie to discuss advances in localised colon cancer

Jenny Seligmann, Professor of Gastrointestinal and Translational Oncology and Honorary Consultant in Medical Oncology at…

Jun 28, 2024, 15:58 | Insight

Updates on BOT/BAL from ESMOGI24

ESMO GI 2024 is held in Munich, Germany, and online from June 26-29. Organized by…

Jun 28, 2024, 13:58 | Societies

EORTC session in gastro-intestinal oncology trials at ESMO GI

The European Organisation for Research and Treatment of Cancer (EORTC) shared on LinkedIn: "Thank you…

Jun 28, 2024, 13:48 | Societies

Peter de Gooyer awarded as the best poster presenter in rectal cancer at ESMOGI24

Chiara Cremolini, Associate Professor in Medical Oncology at the University of Pisa, shared a post…

Jun 28, 2024, 13:48 | Insight

Arndt Vogel: Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at ESMOGI24

Arndt Vogel shared on X: "Neoadjuvant botensilimab + balstilimab in MSI and MSS CRC at…

Jun 28, 2024, 13:41 | Insight

New data from the NEST clinical trial was presented at ESMOGI24 - Agenus

Agenus shared on their X page: "New data from the NEST clinical trial was presented…

Jun 28, 2024, 13:32 | Societies

Updated results from the TRANSMET trial at ESMOGI24

ESMO shared on X: "ESMOGI24: Updated results from the TRANSMET trial showed that chemotherapy combined…

Jun 28, 2024, 13:15 | Insight

The clinical utility of liquid biopsies detecting ctDNA in guiding treatment for patients with mCRC - ESMO

ESMO (European Society for Medical Oncology) shared on LinkedIn: "Data from two presentations at ESMOGI24…

Jun 28, 2024, 13:09 | Insight

Vittorio Studiale: Impressive pathological response rate with neoadjuvant BOT/BAL in MSS CRC

Vittorio Studiale, Medical Oncology Resident at University Hospital of Pisa, shared on X: "Impressive pathological…

Jun 28, 2024, 13:00 | Insight

Cathy Eng: Agenus with very promising data in early MSI-s/MSI-H colon cancer

Cathy Eng shared on X/Twitter: "Bot/Bal immunotherapy in colon cancer NEST 1/2. Agenus with very…

Jun 28, 2024, 12:00 | Societies

Prospective study on the prognostic impact of mutKRAS at ESMOGI24

Giada Grelli, Medical Oncology Resident at University of Pisa, shared on X: "So grateful and…

Jun 28, 2024, 11:47 | Societies

Anwaar Saeed: Thrilled to present mature data from phase 2 CRC expansion cohort

Anwaar Saeed, Associate Professor and Chief of Gastrointestinal Medical Oncology at University of Pittsburgh, shared…

Jun 28, 2024, 11:28 | Societies

Keynote address by Myriam Chalabi at ESMOGI24

Toni Choueiri shared on X: "Keynote address at ESMOGI24 with superstar Myriam Chalabi- Immunotherapy for…

Jun 28, 2024, 11:27 | Societies

12 Posts You Should Not Miss From Day 2 of ESMOGI24!

ESMOGI24 is taking place as an onsite event in Munich, Germany, from 26 to 29 June 2024,…

Jun 28, 2024, 11:14 | Blog

Aparna Parikh: Missing ESMOGI24 but for good reasons

Aparna Parikh shared on X: "Missing ESMOGI24 but for good reasons. Team PROSPECT (Yin Cao,…

Jun 28, 2024, 10:52 | Societies

Learn more about overcoming barriers to immunotherapy for microsatellite stable colorectal cancer

ESMO shared a post on LinkedIn: "ESMOGI24: Colorectal Cancer (CRC) can be classified into two…

Jun 28, 2024, 10:50 | Societies

Rachel Riechelmann: Our multicenter study on colorectal cancer patients treated with CAPOX

Rachel Riechelmann shared on X: "Our multicenter study found that renal dysfunction, age and Olmesartan…

Jun 28, 2024, 10:40 | Societies

The final results of the KEYNOTE-585 study presented at ESMOGI24

ESMO shared on LinkedIn: "The final results of the KEYNOTE-585 study presented at ESMOGI24 suggest…

Jun 28, 2024, 08:19 | Societies

15 Posts You Should Not Miss From The 1st Day of ESMOGI24

ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29…

Jun 28, 2024, 00:56 | Blog

Mark Lewis: This is the football/oncology crossover I’m here for

Mark Lewis shared a post on X: “This is the football/oncology crossover I’m here for,…

Jun 27, 2024, 14:49 | Societies

ESMOGI24 Presentations Summarized By Megan Barnet

ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29…

Jun 27, 2024, 14:31 | Societies

Keep up with ESMOGI24 with Teresa Macarulla

ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26 to 29…

Jun 27, 2024, 12:44 | Societies

Discuss the future of immuno-oncology with Agenus at ESMOGI24

Agenus shared on LinkedIn: "If you are a physician attending ESMOGI24 in Munich from June…

Jun 27, 2024, 10:23 | Insight

ESMO announces the the ESMO GI Ambassadors

The European Society for Medical Oncology (ESMO) shared on LinkedIn: “ESMOGI24: ESMO is excited to…

Jun 27, 2024, 08:37 | Societies

Angela Lamarca: Subgroup analysis on NETTER2

Angela Lamarca, HPB and NET Medical Oncologist at Jimenez Diaz Foundation, shared a post on X:…

Jun 27, 2024, 08:31 | Societies

Arndt Vogel: Phase I study of the PKMYT1 inhibitor lunresertib in combination with FOLFIRI

Arndt Vogel shared on X: "Phase I study of the PKMYT1 inhibitor lunresertib in combination…

Jun 27, 2024, 08:20 | Societies

Insights from ESMOGI24 by Angela Lamarca

ESMO GI 2024 is taking place as an onsite event in Munich, Germany, from 26…

Jun 26, 2024, 13:47 | Societies

177Lu-DOTATATE as a frontline treatment for somatostatin receptor-positive grade 3 low GEP-NETs

ESMO shared on LinkedIn: "ESMOGI24: Promising data from the phase III NETTER-2 study show that…

Jun 26, 2024, 13:38 | Societies

Angela Lamarca: Opening Press Conference at ESMOGI24

Angela Lamarca, HPB and NET Medical Oncologist at Jimenez Diaz Foundation, shared a post by…

Jun 26, 2024, 13:33 | Societies

Nieves Martinez Lago: Real-world efficacy and safety of immune checkpoint inhibitors

Nieves Martinez Lago, Medical Oncologist at University Hospital Complex of Ferrol, shared on X: "Visit…

Jun 26, 2024, 13:27 | Societies

Erman Akkus: Germline mutations are common in non-familial pancreatic cancer

Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X: "Germline mutations…

Jun 26, 2024, 12:40 | Societies

EGFR co-inhibition in KRAS

Megan Barnet, Medical Oncologist at The Kinghorn Cancer Centre, shared on X: "Great summary from…

Jun 26, 2024, 12:19 | Societies

Brilliant keynote lecture on KRAS inhibitors by Dr. Ryan Corcoran at ESMOGI24

Vittorio Studiale, Medical Oncology resident at AOUP, shared on X: "European Championship of gastrointestinal oncology?…

Jun 18, 2024, 23:25 | Insight

The future of immuno-oncology discussion with Agenus at ESMO GI 2024

Agenus shared a post on LinkedIn: “Are you a physician attending ESMO GI 24? Join…

Jun 10, 2024, 06:13 | Blog

Deniz Can Guven: Come and join us at ESMOGI24

Deniz Can Guven, Medical Oncologist at Health Sciences University, Elazığ City Hospital, shared on X: "Less…

Jun 10, 2024, 01:18 | Societies

Last call to register for the ESMOGI24

ESMO - European Society for Medical Oncology shared a post on LinkedIn: "Last call to…

May 15, 2024, 12:21 | Blog

Pashtoon Kasi: We got a podium presentation with an invited discussant at ESMOGI24

Pashtoon Kasi shared on X/Twitter: "We got a podium presentation with an invited discussant at ESMOGI24.…

Apr 13, 2024, 07:04 | Opinion

5 years of research advances in upper GI cancer - ESMO

ESMO shared a post on LinkedIn: "ESMOGI24: From perioperative care to targeted therapy, 5 years of…